IN2015KN00329A - - Google Patents

Info

Publication number
IN2015KN00329A
IN2015KN00329A IN329KON2015A IN2015KN00329A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A IN 329KON2015 A IN329KON2015 A IN 329KON2015A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A
Authority
IN
India
Prior art keywords
compositions
diseases
disclosed
methods
encompass
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher K Garcia
Darren L Bates
Ignacio Moraga
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IN2015KN00329A publication Critical patent/IN2015KN00329A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN329KON2015 2012-08-09 2013-08-08 IN2015KN00329A (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US201361825980P 2013-05-21 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Publications (1)

Publication Number Publication Date
IN2015KN00329A true IN2015KN00329A (enExample) 2015-07-10

Family

ID=50685291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN329KON2015 IN2015KN00329A (enExample) 2012-08-09 2013-08-08

Country Status (6)

Country Link
US (3) US9738696B2 (enExample)
EP (1) EP2882449B1 (enExample)
JP (2) JP6445434B2 (enExample)
CN (2) CN104619334A (enExample)
IN (1) IN2015KN00329A (enExample)
WO (1) WO2014074186A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038533A1 (en) * 2016-09-30 2018-04-05 The Board Of Trustees Of The Leland Stanford Junior University Variant type iii interferons and synthekines
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
CN110582293B (zh) * 2017-03-31 2025-04-04 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
MX2020012248A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CN118108857A (zh) 2018-06-01 2024-05-31 利兰斯坦福初级大学董事会 免疫细胞靶向性构建体
ES3029842T3 (en) 2019-04-19 2025-06-25 Synerkine Pharma B V A fusion protein comprising il13
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4532018A1 (en) * 2022-05-24 2025-04-09 University of Pittsburgh - of the Commonwealth System of Higher Education Interleukin 4 and/or interleukin 13-based eye compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142860A1 (en) 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
AU2001288405B8 (en) 1998-04-03 2007-06-14 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
ES2300276T5 (es) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
CA2386248A1 (en) 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants
CA2404763A1 (en) 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20030013851A1 (en) 2001-06-07 2003-01-16 Robert Powers Solution structure of IL-13 and uses thereof
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
CN101203247A (zh) 2005-01-10 2008-06-18 研究发展基金会 用于癌症治疗的靶向嵌合分子
CA2622504A1 (en) 2005-09-09 2008-03-08 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cel proliferation
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
RU2008152821A (ru) 2006-06-07 2010-07-20 Джензим Корпорейшн (Us) Генная терапия бокового амиотрофического склероза и других заболеваний спинного мозга
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
JP2010536386A (ja) 2007-08-24 2010-12-02 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 受容体標的化試薬
KR20110022604A (ko) 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
EP2352526A1 (en) 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
EP2544169A4 (en) 2010-03-03 2015-04-22 Sharp Kk DISPLAY DEVICE, ITS CONTROL METHOD, AND LIQUID CRYSTAL DISPLAY DEVICE
EP2629788A4 (en) 2010-10-22 2014-03-19 Protox Therapeutics Corp USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
CN107164330A (zh) 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
CA3180148A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
PL3068797T3 (pl) 2013-11-11 2020-06-29 Wake Forest University Health Sciences Konstrukty wielowalentnego celowania w nowotwory
KR102480433B1 (ko) 2014-02-07 2022-12-21 맥마스터 유니버시티 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
SG11201701775VA (en) 2014-09-09 2017-04-27 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
CN113789336B (zh) 2014-09-19 2025-12-16 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
AU2018347796B2 (en) 2017-10-10 2025-07-24 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
JP2022519377A (ja) 2019-02-07 2022-03-23 メディシナ セラピューティクス インコーポレイテッド がんのバイオマーカーとしてのｉｌ－４ｒ
EP4172216A4 (en) 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF

Also Published As

Publication number Publication date
EP2882449A2 (en) 2015-06-17
EP2882449B1 (en) 2019-05-15
EP2882449A4 (en) 2016-03-09
US9738696B2 (en) 2017-08-22
US12187771B2 (en) 2025-01-07
US20160244499A1 (en) 2016-08-25
JP2015525574A (ja) 2015-09-07
US10738096B2 (en) 2020-08-11
US20180016316A1 (en) 2018-01-18
CN104619334A (zh) 2015-05-13
JP2018161143A (ja) 2018-10-18
WO2014074186A3 (en) 2014-06-19
WO2014074186A2 (en) 2014-05-15
JP6445434B2 (ja) 2018-12-26
US20210188932A1 (en) 2021-06-24
CN110615835A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
IN2015KN00329A (enExample)
CY1123106T1 (el) Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2015003140A (es) Formulaciones de enzalutamida.
CR20160576A (es) Anticuerpos dirigidos contra cd127
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
PH12012502369A1 (en) Purinone derivative
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
MX2015014438A (es) Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
MX2016008448A (es) Conjugados de var2csa-farmaco.
PH12012501550A1 (en) Modified tuberculosis antigens
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
CA142107S (en) Log splitting wedge
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2013109055A3 (ko) 개 유래의 자연살해세포 및 이의 대량 증식방법
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas
UA117908C2 (uk) Застосування гепарину або гепарансульфату для індукції пологів
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
CL2015001481A1 (es) Uso de extracto bacopa monnieri
MY175703A (en) Tablets with improved acceptance and good storage stability
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.